Much of this globally valuable capacity was built under a regime of weak – in fact, non-existent – protection for pharmaceutical patents. But India is now bound by the World Trade Organization’s TRIPS agreement, and has revised its patent laws accordingly, causing widespread anxiety in the developing world about the implications for global provision of affordable medicines.